Miliksol solution for infection. 15mg/1.5ml amp. 1.5 ml No. 5

Solution for injections of Miliksol is applied to short-term symptomatic treatment of a bad attack of a pseudorheumatism and an ankylosing spondylitis when oral and rectal ways of use cannot be applied.

Structure

Active ingredient - meloxicam (1.5 ml of solution contain 15 mg of a meloksikam).

Excipients: Megluminum, glikofurol, half-oxameasures 188, sodium chloride, glycine, sodium hydroxide, water for injections.

Contraindication

• III pregnancy trimester;
• age of the patient up to 18 years;
• hypersensitivity to a meloksikam or other components of medicine, or to active agents with similar action, such as NPVP, aspirin (it is not necessary to appoint to patients who had asthma symptoms, nasal polyps, a Quincke's disease or a small tortoiseshell after intake of aspirin or other NPVP);
• gastrointestinal bleeding or the perforation connected with the previous therapy of NPVP in the anamnesis;
• an active or recurrent ulcer / bleeding in the anamnesis (two or more separate confirmed case of an ulcer or bleeding);
• heavy liver failure;
• a heavy renal failure, without dialysis use;
• gastrointestinal bleeding, cerebrovascular bleeding in the anamnesis or other disturbances of blood clotting;
• disorder of a hemostasis or simultaneous use of anticoagulants (the contraindications connected with way of use);
• heavy heart failure;
• treatment of perioperatsionny pain at coronary shunting.

Route of administration

Intramuscular use.

One injection of 15 mg of 1 times a day. Not to exceed a dose of 15 mg/days.

Treatment has to be limited to one injection at the beginning of therapy with the maximum duration up to 2-3 days in reasonable exceptional cases (for example when oral and rectal ways of use are impossible). Side reactions can be minimized by use of the smallest effective dose during the shortest time of the treatment necessary for control of symptoms.

Should estimate periodically need of the patient for symptomatic simplification and its response to treatment.

Way of use

Drug should be administered slowly, by a deep injection in an upper external quadrant of a buttock, adhering to the strict aseptic equipment. In case of repeated introduction it is recommended to change the place of an injection, alternating the left and right buttocks. Before an injection it is important to check that the edge of a needle was not in a vessel.

Injection should be stopped immediately in case of severe pain during an injection.

in case of a prosthesis of a hip joint in other buttock.

Feature of use

Pregnant

Meloksikam, as well as other medicines inhibiting cyclooxygenase/prostaglandin synthesis can have negative effect on reproductive function and is not recommended to women who want to become pregnant. Therefore for women who plan pregnancy or undergo inspection concerning infertility, it is necessary to consider the possibility of cancellation of a meloksikam.

during I and II trimester of pregnancy to meloksika should not be applied, except for emergency. If the woman who tries to become pregnant or during I and II trimester of pregnancy applies to meloksika, the dosage and duration of treatment have to be the slightest. Meloksikam is contraindicated during the III trimester of pregnancy.

specific data on the medicament "Miliksol", NPVP is known that they can get into breast milk. Therefore use is not recommended to women who nurse.

Children

Miliksol, solution for injections of 15 mg / 1.5 the ml, is contraindicated to children (aged up to 18 years).

Drivers

Special researches about influence of medicament on ability to drive the car or to work with other mechanisms. However on the basis of a pharmakodinamichesky profile and side reactions which were observed to meloksika it is inclined not to influence or have insignificant influence on the specified activity. However to patients at whom dysfunctions of sight were observed including illegibility of sight, dizziness, drowsiness, vertigo or other disturbances of the central nervous system, it is recommended to refrain from driving or work with other mechanisms.

Overdose

Symptoms of acute overdose of NPVP are usually limited to a lethargy, drowsiness, nausea, vomiting and epigastric pain which in general are reversible at maintenance therapy. There can be gastrointestinal bleeding. The serious poisoning can lead to arterial hypertension, an acute renal failure, liver dysfunction, respiratory depression, a coma, spasms, cardiovascular insufficiency and cardiac arrest. It was reported about anaphylactoid reactions at therapeutic use of NPVP that it can also be observed at overdose. At overdose of NPVP it is recommended to patients the symptomatic and supporting actions. Researches showed the accelerated removal of a meloksikam by means of 4 oral doses of Colestyraminum 3 times a day.

Given researches and epidemiological data allow to assume

that use of some NPVP (especially in high doses and at long-term treatment) can be connected with small increase in risk of the vascular trombotichesky phenomena (such as myocardial infarction or stroke). Hypostasis, arterial hypertension and heart failure were observed at treatment of NPVP.

Majority of side effects which were observed, gastrointestinal origin. The ulcer, perforation or gastrointestinal bleeding, sometimes lethal, especially at patients of advanced age is possible. After use the nausea, vomiting, diarrhea, a meteorism, a constipation, dyspepsia, abdominal pain, a melena, vomiting by blood, a stomacace, exacerbation of colitis and Crohn's disease were observed. With a smaller frequency the gastritis was observed. It was reported about severe damages of skin: Stephens-Johnson's syndrome and toxic epidermal necrolysis.

Storage conditions

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 5 years.